About the AuthorMy name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
My ProfileI am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!
About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
December 2023 M T W T F S S 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
Category Archives: New and Social Media
One of the many noteworthy milestones with respect to digital has been around the transition to mobile search. As was recently reported, Google’s Amit Singhal speaking at a conference noted that Google is getting over 100 billion searches each month … Continue reading →
This week there was a lot of talk about last week and the meeting of the American Society of Clinical Oncology annual meeting ASCO 15, which was the 51st annual meeting of the society held May 29 – June 2 … Continue reading →
Last week I posted about the update to the database of pharma and social media use with respect to the increase in audience over last year. While FDA’s OPDP was so complacent in coming forth in guidelines, the number of … Continue reading →
It is hard to believe that a service that limits your speech to 140 characters would emerge as an important media platform, but it has. News travels more quickly, is more granular in nature, can very specific to highly targeted … Continue reading →
Someone asked me the other day something to the effect of this – what is the point of social media when it comes to news – isn’t CNN just as fast? It occurred to me that many of us in … Continue reading →